Search

Displaying results 4501 - 4510 of 10000 in total
  1. Drug

    Interferon beta-1b

    go.drugbank.com/drugs/DB00068
    ApprovedInvestigational

    Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD

    Categories: Interferon Type I
  2. Drug

    XL820

    go.drugbank.com/drugs/DB05146
    Investigational

    XL820 is investigated for use/treatment in solid tumors. XL820 is a solid. … a variety of human cancers.

  3. Drug

    Carbutamide

    go.drugbank.com/drugs/DB13406
    Investigational

    Categories: Drugs Used in Diabetes
  4. Drug

    Lorajmine

    go.drugbank.com/drugs/DB13651
    Experimental

    Categories: Antiarrhythmics, Class Ia, Antiarrhythmics, Class I
  5. Drug

    Phenothrin

    go.drugbank.com/drugs/DB13717
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Maxacalcitol

    go.drugbank.com/drugs/DB06272
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline

    go.drugbank.com/drugs/DB02855
    Experimental

    Categories: Compounds used in a research, industrial, or household settingSynonyms: N-(3-Propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline
  8. Drug

    1D09C3

    go.drugbank.com/drugs/DB05121
    Experimental

    1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. … class II-positive tumor cells, which include those in B-cell and T-cell lymphomas. 1D09C3 has been shown to induce programmed cell death and does not require a functioning immune system for its cell-killing

  9. Drug

    Actelion-1

    go.drugbank.com/drugs/DB05367
    Experimental

    Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.

    Categories: Endothelin A Receptor Antagonists
  10. Drug

    CCX915

    go.drugbank.com/drugs/DB05159
    Experimental

    CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders. … The CCR2 receptor is thought to be of central importance to inflammatory diseases, such as multiple sclerosis (MS), Type II diabetes and atherosclerosis.